

April 26, 2023

Name of listed company: Chugai Pharmaceutical Co., Ltd.  
Code number: 4519 (Prime Market of Tokyo Stock Exchange)  
Head office: 1-1, Nihonbashi-Muromachi 2-Chome, Chuo-ku, Tokyo  
President & CEO: Osamu Okuda  
Inquiries to: Toshiya Sasai  
Head of Corporate Communications Dept.  
Tel: +81-(0)3-3273-0554

## **F. Hoffmann-La Roche Announces First Quarter Sales 2023**

F. Hoffmann-La Roche Ltd. (hereafter “Roche”) [Head Office: Basel, Switzerland. CEO: Thomas Schinecker] announced today its first quarter sales 2023 (January 1 – March 31, 2023).

Roche owns 59.89% of Chugai’s outstanding shares (61.14% of voting rights) as of the end of December 2022.

Its investor update and presentation materials can be found on its website (<https://www.roche.com>).

Chugai’s performance for the period of January 1 to March 31, 2023 is included in the announced Roche Group’s results.

[Investor Updates](#)

[Reporting](#)

###